Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.50 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.50 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | PHF8 | Q9UPP1 | 7/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 7/20 | 0.44 |
| ▸ | KDM5C | P41229 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | KDM6B | O15054 | 3/20 | 0.44 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810926 | 1.00 | LMNA (0.52) | LMNASLC15A2EGLN1ALKBH5SUCNR1 | |
| SCHEMBL15363970 | 0.84 | SLC22A6 (0.55) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL15363968 | 0.84 | SLC22A6 (0.55) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL15363963 | 0.84 | LMNA (0.55) | LMNAOR51E2SLC22A6ADRA1ATSHR | |
| Succinic Acid SCHEMBL3872448 | 0.84 | LMNA (0.48) | LMNASLC15A2EGLN1ALKBH5SUCNR1 | |
| SCHEMBL15363966 | 0.84 | LMNA (0.55) | LMNAOR51E2SLC22A6ADRA1ATSHR | |
| SCHEMBL28726986 | 0.82 | TSHR (0.57) | LMNAOR51E2SLC22A6ADRA1ATSHR | |
| SCHEMBL810940 | 0.82 | TSHR (0.57) | LMNAOR51E2SLC22A6ADRA1ATSHR | |
| SCHEMBL811739 | 0.82 | TSHR (0.57) | LMNAOR51E2SLC22A6ADRA1ATSHR | |
| SCHEMBL811493 | 0.82 | TSHR (0.57) | LMNAOR51E2SLC22A6ADRA1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975267-B2 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-10 | — | — | US | disclosed |
| US-20130296305-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-07 | — | — | US | disclosed |
| EP-2389349-A2 | METHODS FOR PRODUCING DODECANEDIOIC ACID AND DERIVATIVES THEREOF | Draths Corporation (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8041434-B2 | Implantable medical electrical lead bodies providing improved electrode contact | MEDTRONIC, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010085712-A2 | METHODS FOR PRODUCING DODECANEDIOIC ACID AND DERIVATIVES THEREOF | DRATHS CORPORATION (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-1994023836-A1 | CATALYST COMPOSITION AND PROCESS FOR THE PRODUCTION OF UNSATURATED DIESTERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-10-27 | — | — | WO | disclosed |
| US-4638084-A | BIS (THYLENE) RHODIUM TETRAFLUOROBORATE CATALYST | SHELL OIL COMPANY (US) | 1987-01-20 | — | — | US | disclosed |
| US-4451665-A | Process for dimerizing acrylates and methacrylates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296305-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | LMNA 2365/4885SLC15A2 4630/4885EGLN1 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.